These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 33472913)
1. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). Crabb SJ; Danson S; Catto JWF; Hussain S; Chan D; Dunkley D; Downs N; Marwood E; Day L; Saunders G; Light M; Whitehead A; Ellis D; Sarwar N; Enting D; Birtle A; Johnson B; Huddart R; Griffiths G Clin Cancer Res; 2021 Apr; 27(7):1882-1892. PubMed ID: 33472913 [TBL] [Abstract][Full Text] [Related]
2. SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. Crabb S; Danson SJ; Catto JWF; McDowell C; Lowder JN; Caddy J; Dunkley D; Rajaram J; Ellis D; Hill S; Hathorn D; Whitehead A; Kalevras M; Huddart R; Griffiths G Trials; 2018 Apr; 19(1):216. PubMed ID: 29615077 [TBL] [Abstract][Full Text] [Related]
3. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526 [TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Hussain SA; Stocken DD; Riley P; Palmer DH; Peake DR; Geh JI; Spooner D; James ND Br J Cancer; 2004 Aug; 91(5):844-9. PubMed ID: 15292922 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365 [TBL] [Abstract][Full Text] [Related]
6. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978 [TBL] [Abstract][Full Text] [Related]
7. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Galsky MD; Posner M; Holcombe RF; Lee KM; Misiukiewicz K; Tsao CK; Godbold J; Soto R; Gimpel-Tetra K; Lowe N; Oh WK Cancer Chemother Pharmacol; 2014 Sep; 74(3):465-71. PubMed ID: 25023489 [TBL] [Abstract][Full Text] [Related]
8. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. Hutson TE; Vukelja S; Atienza D; Awasthi S; Delaune R; Deutsch M; Dien PY; Gregory TF; Kolodziej MJ; Muscato JJ; Raju RN; Ruxer RL; Mull S; Ilegbodu D; Hood K; Nicol S; Berry W Invest New Drugs; 2008 Apr; 26(2):151-8. PubMed ID: 18236006 [TBL] [Abstract][Full Text] [Related]
10. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452 [TBL] [Abstract][Full Text] [Related]
11. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976 [TBL] [Abstract][Full Text] [Related]
14. Tolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly Population. Jan AS; Dolan DE; Lombardi K; Gupta S Clin Genitourin Cancer; 2016 Jun; 14(3):e257-63. PubMed ID: 26462439 [TBL] [Abstract][Full Text] [Related]
15. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma]. Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Caffo O; Fellin G; Graffer U; Valduga F; Bolner A; Luciani L; Tomio L; Galligioni E Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1310-6. PubMed ID: 14630267 [TBL] [Abstract][Full Text] [Related]
17. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S; Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138 [TBL] [Abstract][Full Text] [Related]
18. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229 [TBL] [Abstract][Full Text] [Related]
19. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder. DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506 [TBL] [Abstract][Full Text] [Related]
20. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study. Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]